Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Power List / 2015 / The Top 100 Most Influential People / Jean Luc Veuthey

Jean-Luc Veuthey

Professor, School of pharmaceutical sciences, University of Geneva, Switzerland.

  • Profile

Meet Jean-Luc Veuthey

Most important lesson The importance of the scientific collaborations between colleagues from different domains to achieve relevant results.

Funniest/most unexpected moment My nomination as a full professor while I was a young scientist working in a pharmaceutical company.

Eye on the horizon We will not modify our main area of research (development of separation methods dedicated to pharmaceutical compounds), but the importance of new biopharmaceuticals will certainly increase in the coming years, inducing the implementation of new techniques for these complex compounds. The size of the group will remain the same but we must begin new partnerships with the industry, especially to face the analytical challenge of biopharmaceuticals.

I see the development of new stationary phases in LC for increasing the analytical performance (for example, monolithic materials, pillar array) and the miniaturization of equipment.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.